-
Innovation Ranking
NewInnovation Ranking – Jiangsu Hengrui Medicine Co Ltd
Jiangsu Hengrui Medicine Co Ltd (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its...
-
Product Insights
Anhui Hengrui Solar PV Plant
Anhui Hengrui Solar PV Plant is a solar PV project located in Anhui, China. The project came online in 2014. Empower your strategies with our Anhui Hengrui Solar PV Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data...
-
Sector Analysis
NewAntibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products, Opportunities and Challenges
Antibody-Drug Conjugates Market Report Overview An Antibody-Drug Conjugates (ADC) drug consists of monoclonal antibodies conjugated to a payload via a linker, for the precise targeting of antigen-positive cancer cells. ADCs are developed to target protein receptors with high expression such as HER2, TROP-2, CD22, and others. There are two cytotoxic payload types predominantly used in ADCs including microtubule inhibitors, and the more potent DNA-damaging payloads such as topoisomerase I inhibitors. The ADC market research report will aid clients in gaining...
-
Company Insights
Innovation and Patenting activity of Jiangsu Hengrui Medicine Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Jiangsu Hengrui Medicine Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SHR-1819 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SHR-1819 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SHR-1819 in Atopic Dermatitis (Atopic Eczema) Drug Details: SHR-1819...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SHR-1819 in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SHR-1819 in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SHR-1819 in Asthma Drug Details: SHR-1819 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Recaticimab in Hyperlipidemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Recaticimab in Hyperlipidemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Recaticimab in Hyperlipidemia Drug Details: Recaticimab (SHR-1209) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HRS-5965 in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HRS-5965 in Lupus Nephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HRS-5965 in Lupus Nephritis Drug Details: HRS-5965 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HRS-5965 in IgA Nephropathy (Berger’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HRS-5965 in IgA Nephropathy (Berger's Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HRS-5965 in IgA Nephropathy (Berger's Disease) Drug Details: HRS-5965 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dexmedetomidine Hydrochloride 1 in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dexmedetomidine Hydrochloride 1 in Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dexmedetomidine Hydrochloride 1 in Pain Drug Details: Dexmedetomidine hydrochloride is a...